Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × Neoadjuvant Therapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 37 Colorectal Neoplasms 23 Carcinoma, Non-Small-Cell Lung 18 Rectal Neoplasms 14 Lung Neoplasms 13 Stomach Neoplasms 8 Esophageal Neoplasms 8 Colonic Neoplasms 8 Carcinoma, Hepatocellular 8 Pancreatic Neoplasms 7 Esophageal Squamous Cell Carcinoma 7 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Adenocarcinoma Of Esophagus 6 Squamous Cell Carcinoma of Head and Neck 5 Osteosarcoma 5 Neoplasms 5 Liver Neoplasms 5 Sarcoma 4 Inflammatory Breast Neoplasms 4 Fallopian Tube Neoplasms 4 Breast Neoplasms, Male 4 Urinary Bladder Neoplasms 3 Turcot syndrome 3 Multiple Myeloma 3 Locally Advanced Rectal Cancer 3 Head and Neck Neoplasms 3 Adenocarcinoma of Lung 3 Uterine Cervical Neoplasms 2

Interventions

osimertinib 5 Carboplatin 5 Drug Therapy 4 tislelizumab 3 anlotinib 3 aflutinib 3 Radiotherapy 3 Pemetrexed 3 toripalimab 2 pembrolizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Radiosurgery 2 Paclitaxel 2 HM781-36B 2 Cisplatin 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1 camrelizumab 1 brigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡